Abstract The Epidermal Growth Factor Receptor (EGFR) is selectively expressed on the
surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and head and …

The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a
variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been …

Background Cetuximab, the first approved EGFR targeting therapeutic antibody, is currently
used to treat colorectal cancer and head and neck cancer. While effective, cetuximab is …

Epidermal growth factor receptor (EGFR) over-signaling leads to more aggressive tumor
growth. The antitumor effect of Cetuximab, an anti-EGFR antibody, depends on oncogenic …

Cetuximab is a chimeric mouse–human monoclonal antibody that targets the human
epidermal growth factor receptor (EGFR). However, EGFR expression determined by …

Cetuximab is a chimeric immunoglobulin G1 monoclonal antibody that targets the
extracellular domain of the epidermal growth factor receptor (EGFR) with high specificity and …

Despite clinical efficacy, current approved agents targeting EGFR are associated with on-
target toxicities as a consequence of disrupting normal EGFR function. MAb 806 is a novel …

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor
involved in the proliferation and survival of cancer cells. EGFR is the first molecular target …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

Epidermal Growth Factor Receptor (EGFR) overexpression or its mutation mediates the
sustaining proliferative signaling, which is an important hallmark of cancer. Human EGFR …